Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

This Phase 1/2a study evaluated the safety, immunogenicity, and efficacy of an experimental malaria vaccine comprised of the recombinant Plasmodium falciparum protein apical membrane antigen-1 (AMA-1) representing the 3D7 allele formulated with either the AS01B or AS02A Adjuvant Systems.After a prel...

Full description

Bibliographic Details
Main Authors: Michele D Spring, James F Cummings, Christian F Ockenhouse, Sheetij Dutta, Randall Reidler, Evelina Angov, Elke Bergmann-Leitner, V Ann Stewart, Stacey Bittner, Laure Juompan, Mark G Kortepeter, Robin Nielsen, Urszula Krzych, Ev Tierney, Lisa A Ware, Megan Dowler, Cornelus C Hermsen, Robert W Sauerwein, Sake J de Vlas, Opokua Ofori-Anyinam, David E Lanar, Jack L Williams, Kent E Kester, Kathryn Tucker, Meng Shi, Elissa Malkin, Carole Long, Carter L Diggs, Lorraine Soisson, Marie-Claude Dubois, W Ripley Ballou, Joe Cohen, D Gray Heppner
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2669163?pdf=render

Internet

http://europepmc.org/articles/PMC2669163?pdf=render

Similar Items